Amiloride inhibits osteoclastogenesis by suppressing nuclear factor-κB and mitogen-activated protein kinase activity in receptor activator of nuclear factor-κB-induced RAW264.7 cells

Wang,Xiangdong; Zhu,Yuanli; Zheng,Shouchao; Ni,Chaochao; Zhao,Libo; Liu,Changyu; Chen,Anmin; Xiao,Jun

doi:10.3892/mmr.2015.3204

Amiloride inhibits osteoclastogenesis by suppressing nuclear factor-κB and mitogen-activated protein kinase activity in receptor activator of nuclear factor-κB-induced RAW264.7 cells

Authors:
- Xiangdong Wang
- Yuanli Zhu
- Shouchao Zheng
- Chaochao Ni
- Libo Zhao
- Changyu Liu
- Anmin Chen
- Jun Xiao
View Affiliations

Affiliations: Department of Orthopedics, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Pathology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Spine and Joints, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Hebei Medical University, Cangzhou, Hebei 061001, P.R. China, Department of Endocrinology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Orthopedics, Liyuan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: January 15, 2015 https://doi.org/10.3892/mmr.2015.3204
Pages: 3451-3456

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Amiloride is widely used in clinical practice as a diuretic and is known to interact with the epithelial sodium channel and acid‑sensing ion channel proteins, as well as Na+/H+ antiporters and Na+/Ca2+ exchangers. The aim of the present study was to examine the effects of amiloride on receptor activator of nuclear factor‑κB ligand (RANKL)‑induced osteoclastogenesis and to elucidate the underlying mechanisms in the RAW264.7 murine macrophage cell line. The number of tartrate‑resistant acid phosphatase (TRAP)‑positive multinucleated cells were counted and the bone resorption area was estimated. In addition the expression levels of nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) mRNA and osteoclast‑specific genes, including TRAP, matrix metalloproteinase 9, cathepsin K and osteoclast‑associated receptor, were examined using reverse transcription‑quantitative polymerase chain reaction. The nuclear factor‑κB (NF‑κB) and mitogen‑activated protein kinase (MAPK) signaling pathways were also investigated using western blotting. The results showed that amiloride significantly reduced the number of TRAP‑positive multinucleated cells as well as the bone resorption area. Amiloride also downregulated the expression of NFATc1 mRNA and inhibited the expression of osteoclast‑specific genes. A possible underlying mechanism may be that amiloride suppresses the degradation of the inhibitor of NF‑κB and blocks the activation of c‑Jun N‑terminal kinase, extracellular signal‑regulated kinase and p38, thus implicating the NF‑κB and MAPK pathway is this process. In conclusion, the current data suggest that amiloride is a strong inhibitor of osteoclast differentiation, indicating a novel indication for amiloride in the treatment of bone‑loss‑related diseases.

View Figures

View References

1	Suda T, Takahashi N and Martin TJ: Modulation of osteoclast differentiation. Endocr Rev. 13:66–80. 1992.PubMed/NCBI
2	Zaidi M: Skeletal remodeling in health and disease. Nat Med. 13:791–801. 2007. View Article : Google Scholar : PubMed/NCBI
3	Moon SJ, Ahn IE, Jung H, et al: Temporal differential effects of proinflammatory cytokines on osteoclastogenesis. Int J Mol Med. 31:769–777. 2013.PubMed/NCBI
4	Lippuner K, von Overbeck J, Perrelet R, Bosshard H and Jaeger P: Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos Int. 7:414–425. 1997. View Article : Google Scholar : PubMed/NCBI
5	Rodan GA and Martin TJ: Therapeutic approaches to bone diseases. Science. 289:1508–1514. 2000. View Article : Google Scholar : PubMed/NCBI
6	Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 20:345–357. 1999. View Article : Google Scholar : PubMed/NCBI
7	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
8	Takayanagi H, Kim S, Koga T, et al: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 3:889–901. 2002. View Article : Google Scholar : PubMed/NCBI
9	Kim N, Takami M, Rho J, Josien R and Choi Y: A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med. 195:201–209. 2002.PubMed/NCBI
10	Teitelbaum SL and Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet. 4:638–649. 2003. View Article : Google Scholar : PubMed/NCBI
11	Benos DJ: Amiloride: a molecular probe of sodium transport in tissues and cells. Am J Physiol. 242:C131–C145. 1982.PubMed/NCBI
12	Cragoe EJ Jr, Woltersdorf OW Jr, Bicking JB, Kwong SF and Jones JH: Pyrazine diuretics. II N-amidino-3-amino-5-substituted 6-halopyrazinecarboxamides. J Med Chem. 10:66–75. 1967. View Article : Google Scholar : PubMed/NCBI
13	Canessa CM, Schild L, Buell G, et al: Amiloride-sensitive epithelial Na⁺ channel is made of three homologous subunits. Nature. 367:463–467. 1994. View Article : Google Scholar : PubMed/NCBI
14	Kleyman TR and Cragoe EJ Jr: Amiloride and its analogs as tools in the study of ion transport. J Membr Biol. 105:1–21. 1988. View Article : Google Scholar : PubMed/NCBI
15	Ugawa S, Ueda T, Ishida Y, Nishigaki M, Shibata Y and Shimada S: Amiloride-blockable acid-sensing ion channels are leading acid sensors expressed in human nociceptors. J Clin Invest. 110:1185–1190. 2002. View Article : Google Scholar : PubMed/NCBI
16	Jahr H, van Driel M, van Osch GJ, Weinans H and van Leeuwen JP: Identification of acid-sensing ion channels in bone. Biochem Biophys Res Commun. 337:349–354. 2005. View Article : Google Scholar : PubMed/NCBI
17	Li X, Xu RS, Jiang DL, et al: Acid-sensing ion channel 1a is involved in acid-induced osteoclastogenesis by regulating activation of the transcription factor NFATc1. FEBS Lett. 587:3236–3242. 2013. View Article : Google Scholar : PubMed/NCBI
18	Rousselle AV and Heymann D: Osteoclastic acidification pathways during bone resorption. Bone. 30:533–540. 2002. View Article : Google Scholar : PubMed/NCBI
19	Li JP, Kajiya H, Okamoto F, Nakao A, Iwamoto T and Okabe K: Three Na⁺/Ca²⁺ exchanger (NCX) variants are expressed in mouse osteoclasts and mediate calcium transport during bone resorption. Endocrinology. 148:2116–2125. 2007. View Article : Google Scholar : PubMed/NCBI
20	Cuetara BL, Crotti TN, O’Donoghue AJ and McHugh KP: Cloning and characterization of osteoclast precursors from the RAW264.7 cell line. In Vitro Cell Dev Biol Anim. 42:182–188. 2006. View Article : Google Scholar : PubMed/NCBI
21	Wada T, Nakashima T, Hiroshi N and Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 12:17–25. 2006. View Article : Google Scholar
22	Takayanagi H: Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 7:292–304. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 109(Suppl): S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
24	Matsumoto M, Sudo T, Saito T, Osada H and Tsujimoto M: Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappaB ligand (RANKL). J Biol Chem. 275:31155–31161. 2000. View Article : Google Scholar : PubMed/NCBI
25	Ikeda F, Matsubara T, Tsurukai T, Hata K, Nishimura R and Yoneda T: JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. J Bone Miner Res. 23:907–914. 2008. View Article : Google Scholar : PubMed/NCBI
26	Lee SE, Woo KM, Kim SY, et al: The phosphatidylinositol 3-kinase, p38 and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone. 30:71–77. 2002. View Article : Google Scholar : PubMed/NCBI
27	Asagiri M and Takayanagi H: The molecular understanding of osteoclast differentiation. Bone. 40:251–264. 2007. View Article : Google Scholar